Sensars secures EUR 1.1 million in funding to advance revolutionary neuromodulation technology
12.06.2024
Sensars, a leader in neuromodulation technology, has successfully secured EUR 1.1 million in funding to boost the development of its innovative SENSY product. The funding will help Sensars develop advanced solutions for chronic pain relief, bringing new hope to millions of sufferers worldwide.
 SansArs' Co-Founder and CEO Francesco Petrini
|
 |
The Medtech startup Sensars has received pre-seed investment from HTH, a VC firm focused on human health, to support the development of solutions for chronic pain.
Additionally, Sensars launched the Eurostars project SENSOLE with a EUR 500,000 grant, aimed at creating the first system for monitoring and treating gait disabilities and pain in patients with leg neuropathy-induced sensory loss. SENSOLE uses wearable sensors to collect data on leg movement and pressure points, which combined with a neurostimulator, helps restore real-time sensory feedback and offers personalized treatment through AI-driven software.
Sensars Germany, a subsidiary of Sensars, secured a EUR 600,000 grant from BMBF to test SENSY, an implantable neurostimulator, in amputees. This project, in collaboration with the University of Heidelberg, aims to improve pain management for amputees, reinforcing Sensars' commitment to innovative neuromodulation solutions.
Sensars won the final stage of Venture Kick, participated in Venture Leaders Life Sciences, and was ranked among the TOP 100 Swiss Startups in 2017.
SansArs' Co-Founder and CEO Francesco Petrini
Additionally, Sensars launched the Eurostars project SENSOLE with a EUR 500,000 grant, aimed at creating the first system for monitoring and treating gait disabilities and pain in patients with leg neuropathy-induced sensory loss. SENSOLE uses wearable sensors to collect data on leg movement and pressure points, which combined with a neurostimulator, helps restore real-time sensory feedback and offers personalized treatment through AI-driven software.
Sensars Germany, a subsidiary of Sensars, secured a EUR 600,000 grant from BMBF to test SENSY, an implantable neurostimulator, in amputees. This project, in collaboration with the University of Heidelberg, aims to improve pain management for amputees, reinforcing Sensars' commitment to innovative neuromodulation solutions.
Sensars won the final stage of Venture Kick, participated in Venture Leaders Life Sciences, and was ranked among the TOP 100 Swiss Startups in 2017.
"Experience the challenge of pitching your idea 20 times a day, learn from the best and most complete startup ecosystem in Life Sciences in the world, and return with the experience and feedback to bring your startup to the next level," highlighted Francesco Petrini, Co-Founder and CEO of SensArs.
SansArs' Co-Founder and CEO Francesco Petrini